Overview on the role of preoperative therapy in the management of kidney cancer

T. Assi, E. El Rassy, F. Farhat, J. Kattan

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

4 Citations (Scopus)

Résumé

The advent of molecular therapy through targeted kinase inhibitors (TKI) has revolutionized the management of renal cell carcinoma. Although surgical resection remains the cornerstone of any therapeutic plan, an increased risk of morbidity and mortality can be of concern in large and complex bulky tumors. Preoperative therapy with TKIs is hypothesized to facilitate resectability, reduce surgical morbidity and allow nephron-sparing surgery. Many concerns on the safety, efficacy and tolerability of these agents before surgery have halted the progress in this setting. In this paper, we will review the indications and safety of preoperative TKIs in RCC as well as the future approaches.

langue originaleAnglais
Pages (de - à)11-20
Nombre de pages10
journalClinical and Translational Oncology
Volume22
Numéro de publication1
Les DOIs
étatPublié - 1 janv. 2020
Modification externeOui

Contient cette citation